S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
66,000% upside on tiny biotech? (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
66,000% upside on tiny biotech? (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
The single greatest medical breakthrough of all time? (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
A fight over precious groundwater in a rural California town is rooted in carrots
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
66,000% upside on tiny biotech? (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
66,000% upside on tiny biotech? (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
The single greatest medical breakthrough of all time? (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
A fight over precious groundwater in a rural California town is rooted in carrots
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
66,000% upside on tiny biotech? (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
66,000% upside on tiny biotech? (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
The single greatest medical breakthrough of all time? (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
A fight over precious groundwater in a rural California town is rooted in carrots
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
66,000% upside on tiny biotech? (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
66,000% upside on tiny biotech? (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
The single greatest medical breakthrough of all time? (Ad)
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
A fight over precious groundwater in a rural California town is rooted in carrots
NASDAQ:NBRV

Nabriva Therapeutics (NBRV) Stock Forecast, Price & News

$0.45
+0.03 (+7.14%)
(As of 09/29/2023 ET)
Compare
Today's Range
$0.42
$0.50
50-Day Range
$0.41
$1.62
52-Week Range
$1.22
$8.45
Volume
7,256 shs
Average Volume
29,344 shs
Market Capitalization
$14.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

NBRV stock logo

About Nabriva Therapeutics (NASDAQ:NBRV) Stock

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

NBRV Price History

NBRV Stock News Headlines

Elon Did It Again: This Could be Bigger than Tesla
Love him or hate him, it’s hard to deny Elon Musk is a genius. After revolutionizing online payment processing (PayPal), space exploration (SpaceX), and the auto industry (Tesla)... He’s getting ready to do it again with his new AI venture.
StockNews.com Begins Coverage on Nabriva Therapeutics (NASDAQ:NBRV)
NBRV - Nabriva Therapeutics plc
U.S. "Shadow Banks" About to Blow up again?
Analyst who called Lehman crash says our biggest calamities (1907, 1929, 2007, etc) all start in the same spot--and it’s about to happen again. More here.
NBRV Nabriva Therapeutics plc
Nabriva Therapeutics Provides Corporate Update
Nabriva's stock is up after sharing antibiotic news
See More Headlines
Receive NBRV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nabriva Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NBRV Company Calendar

Last Earnings
5/06/2021
Today
10/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NBRV
Employees
39
Year Founded
N/A

Profitability

Net Income
$-57,190,000.00
Net Margins
-148.11%
Pretax Margin
-144.78%

Debt

Sales & Book Value

Annual Sales
$35.59 million
Book Value
$0.10 per share

Miscellaneous

Free Float
31,493,000
Market Cap
$14.41 million
Optionable
Optionable
Beta
1.53
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Colin Broom M.D. (Age 67)
    Director
    Comp: $40k
  • Mr. J. Christopher Naftzger BAMr. J. Christopher Naftzger BA (Age 56)
    Esq., J.D., Interim CEO, Gen. Counsel & Sec.
  • Mr. Daniel Dolan (Age 46)
    Chief Financial Officer













NBRV Stock - Frequently Asked Questions

Should I buy or sell Nabriva Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street research analysts is that investors should "sell" NBRV shares.
View NBRV analyst ratings
or view top-rated stocks.

How have NBRV shares performed in 2023?

Nabriva Therapeutics' stock was trading at $1.89 on January 1st, 2023. Since then, NBRV shares have decreased by 76.2% and is now trading at $0.45.
View the best growth stocks for 2023 here
.

How were Nabriva Therapeutics' earnings last quarter?

Nabriva Therapeutics plc (NASDAQ:NBRV) issued its quarterly earnings results on Thursday, May, 6th. The biotechnology company reported ($13.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($16.75) by $3.50. The biotechnology company earned $2.53 million during the quarter, compared to analyst estimates of $2.25 million. Nabriva Therapeutics had a negative trailing twelve-month return on equity of 365.53% and a negative net margin of 148.11%.
Read the conference call transcript
.

When did Nabriva Therapeutics' stock split?

Shares of Nabriva Therapeutics reverse split on the morning of Friday, September 16th 2022. The 1-25 reverse split was announced on Friday, September 16th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Nabriva Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nabriva Therapeutics investors own include SCYNEXIS (SCYX), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Dynavax Technologies (DVAX), Acasti Pharma (ACST), Amarin (AMRN), AcelRx Pharmaceuticals (ACRX), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and Heat Biologics (HTBX).

What is Nabriva Therapeutics' stock symbol?

Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV."

How do I buy shares of Nabriva Therapeutics?

Shares of NBRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nabriva Therapeutics' stock price today?

One share of NBRV stock can currently be purchased for approximately $0.45.

How much money does Nabriva Therapeutics make?

Nabriva Therapeutics (NASDAQ:NBRV) has a market capitalization of $14.41 million and generates $35.59 million in revenue each year. The biotechnology company earns $-57,190,000.00 in net income (profit) each year or ($19.20) on an earnings per share basis.

How can I contact Nabriva Therapeutics?

Nabriva Therapeutics' mailing address is 25-28 NORTH WALL QUAY IFSC, DUBLIN L2, 19406. The official website for the company is www.nabriva.com. The biotechnology company can be reached via phone at (531) 649-2000, via email at david.garrett@nabriva.com, or via fax at 610-816-6639.

This page (NASDAQ:NBRV) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -